Capricor Therapeutics (CAPR) Total Liabilities (2010 - 2026)

Capricor Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $47.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 82.16% year-over-year to $47.6 million in Q1 2026; TTM through Mar 2026 was $47.6 million, a 82.16% increase from a year earlier, with the FY2025 full-year figure at $50.2 million, up 100.48% from the prior year.
• Total Liabilities retreated to $47.6 million in Q1 2026 per CAPR's latest filing, from $50.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $50.2 million in Q4 2025 and bottomed at $24.7 million in Q3 2024.
• The 5-year median for Total Liabilities is $38.5 million (2022), against an average of $36.8 million.
• Across the five-year window, Total Liabilities surged 504.94% in 2022 and plunged 38.14% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $38.3 million in 2022, then retreated by 5.68% to $36.1 million in 2023, then slumped by 30.76% to $25.0 million in 2024, then soared by 100.48% to $50.2 million in 2025, then dropped by 5.14% to $47.6 million in 2026.
• Per Business Quant, the three latest CAPR Total Liabilities figures stand at $47.6 million (Q1 2026), $50.2 million (Q4 2025), and $42.6 million (Q3 2025).